LIDOCAINE HYDROCHLORIDE INJECTION

The Defense Logistics Agency awarded a firm-fixed-price contract to DMS PHARMACEUTICAL GROUP INC (CAGE 1UNB0) for the delivery of one package of LIDOCAINE HYDROCHLORIDE INJECTION, identified by NSN 6505015332656 and NDC code NDC00409-1323-05, manufactured by Fresenius Kabi USA, LLC, at a total price of $46.86. The award, issued on July 15, 2026, under solicitation SPE2D226F3016 and associated with delivery order SPE2DX25D9822, reflects a single-line-item transaction with zero tolerance for quantity variance, meaning exactly one package must be delivered. Delivery is specified to FOB destination at USS ILLINOIS SSN-786, FPO AP 96694, with the contractor responsible for all transportation costs, risks, and final inspection at the point of delivery. The contract adheres to DLA procurement notes C19 and C20 and requires labeling with CAGE, NSN, PR, and NDC codes, though specific packaging, preservation, or labeling standards such as MIL-STD-129 or MIL-STD-2073-1D are not explicitly defined. The awardee is classified under NAICS 424210 for pharmaceutical wholesale, with no socioeconomic certifications or size status disclosed. No provisions for contract administration, invoicing methods, payment offices, or point of contact details are provided, and no FAR clauses or attachments are listed in the available documentation. Medical substitution is permitted under RANK 01, aligning with military pharmaceutical protocols, and no options, modifications, or performance period beyond the delivery date of July 15, 2026, are included.